About
Products
Knolens
KnolScapes
Knolens
Knolens SLR
Knolens
KnolQuest
Knolens
Edge
Knolens
DataNexus
Platform
Solutions
KnolSights
Experience Knolens
Mythic Therapeutics Presents Positive Phase 1 Data for MYTX-011 in NSCLC
Mythic Therapeutics announced positive efficacy data from the Phase 1 KisMET-01 study of MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in ...
Copyright © 2025. All rights reserved
About
Terms of Service
Privacy Policy
Home/
KnloSights/
Clinical Trial Updates/
Mythic Therapeutics Presents Positive Phase 1 Data for MYTX-011 in NSCLC